Stocks
Intellia Therapeutics Financial Statements (NTLA) |
||||||||||
| Intellia Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 26.02.2021 | 24.02.2022 | 23.02.2023 | 22.02.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 43.1 | 58.0 | 33.1 | 52.1 | 36.3 | 56.4 | |||
| Operating Income, bln rub | -106.4 | -136.6 | -267.9 | -458.2 | -515.3 | -517.3 | ||||
| EBITDA, bln rub | ? | -100.8 | -136.6 | -267.9 | -444.7 | -506.2 | -512.4 | |||
| Net profit, bln rub | ? | -92.7 | -125.6 | -259.7 | -490.2 | -481.2 | -485.5 | |||
| OCF, bln rub | ? | -103.2 | -49.9 | -225.0 | -333.3 | -394.1 | -405.4 | |||
| CAPEX, bln rub | ? | 6.79 | 3.59 | 12.8 | 58.4 | 14.0 | 12.7 | |||
| FCF, bln rub | ? | -110.0 | -53.5 | -237.8 | -391.7 | -408.1 | -418.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 149.5 | 194.6 | 300.9 | 510.3 | 551.6 | 567.4 | ||||
| Cost of production, bln rub | 108.4 | 150.4 | 6.89 | 7.57 | 8.98 | 9.44 | ||||
| R&D, bln rub | 108.4 | 150.4 | 229.8 | 420.0 | 435.1 | 447.3 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 8.54 | 0.000 | 8.83 | ||||
| Assets, bln rub | 334.3 | 676.3 | 1 294 | 1 520 | 1 301 | 1 260 | ||||
| Net Assets, bln rub | ? | 269.9 | 527.1 | 1 040 | 1 236 | 1 050 | 1 036 | |||
| Debt, bln rub | 18.4 | 39.3 | 74.0 | 130.7 | 115.3 | 110.9 | ||||
| Cash, bln rub | 279.7 | 597.4 | 1 086 | 1 262 | 912.2 | 791.3 | ||||
| Net debt, bln rub | -261.4 | -558.1 | -1 012 | -1 131 | -796.9 | -680.4 | ||||
| Ordinary share price, rub | 14.7 | 54.4 | 118.2 | 34.9 | 30.5 | 26.5 | ||||
| Number of ordinary shares, mln | 47.2 | 56.0 | 70.9 | 77.0 | 88.8 | 95.5 | ||||
| Market cap, bln rub | 693 | 3 046 | 8 383 | 2 686 | 2 707 | 2 530 | ||||
| EV, bln rub | ? | 432 | 2 488 | 7 370 | 1 554 | 1 910 | 1 849 | |||
| Book value, bln rub | 270 | 527 | 1 040 | 1 236 | 1 050 | 1 036 | ||||
| EPS, rub | ? | -1.96 | -2.24 | -3.66 | -6.37 | -5.42 | -5.08 | |||
| FCF/share, rub | -2.33 | -0.96 | -3.35 | -5.09 | -4.60 | -4.38 | ||||
| BV/share, rub | 5.71 | 9.41 | 14.7 | 16.1 | 11.8 | 10.8 | ||||
| EBITDA margin, % | ? | -233.8% | -235.5% | -810.4% | -853.2% | -1 395% | -907.8% | |||
| Net margin, % | ? | -215.1% | -216.5% | -785.8% | -940.5% | -1 327% | -860.2% | |||
| FCF yield, % | ? | -15.9% | -1.76% | -2.84% | -14.6% | -15.1% | -16.5% | |||
| ROE, % | ? | -34.3% | -23.8% | -25.0% | -39.7% | -45.8% | -46.9% | |||
| ROA, % | ? | -27.7% | -18.6% | -20.1% | -32.2% | -37.0% | -38.5% | |||
| P/E | ? | -7.48 | -24.3 | -32.3 | -5.48 | -5.62 | -5.21 | |||
| P/FCF | -6.30 | -56.9 | -35.3 | -6.86 | -6.63 | -6.05 | ||||
| P/S | ? | 16.1 | 52.5 | 253.6 | 51.5 | 74.6 | 44.8 | |||
| P/BV | ? | 2.57 | 5.78 | 8.06 | 2.17 | 2.58 | 2.44 | |||
| EV/EBITDA | ? | -4.28 | -18.2 | -27.5 | -3.50 | -3.77 | -3.61 | |||
| Debt/EBITDA | 2.59 | 4.09 | 3.78 | 2.54 | 1.57 | 1.33 | ||||
| R&D/CAPEX, % | 1 596% | 4 195% | 1 802% | 719.3% | 3 111% | 3 533% | ||||
| CAPEX/Revenue, % | 15.8% | 6.18% | 38.6% | 112.0% | 38.6% | 22.4% | ||||
| Intellia Therapeutics shareholders | ||||||||||
